Application of combination of IRAK1 inhibitor and PARP inhibitor in preparation of anti-tumor medicament

The invention provides application of combination of an IRAK1 inhibitor and a PARP inhibitor in preparation of an anti-tumor medicament, and relates to the technical field of biological medicines. According to the application disclosed by the invention, the IRAK1 is found to be capable of promoting the generation of NBS1 phosphorylation in IRAK1 high-expression tumors, so that the DNA homologous recombination repair efficiency is further improved, and the treatment of a PARP inhibitor is insensitive; if the enzyme activity of IRAK1 is inhibited, NBS1 phosphorylation is reduced, the homologous recombination repair efficiency is reduced, and at the moment, the PRAP inhibitor is combined for use, so that an obvious synthetic lethal effect is achieved. According to the invention, a novel treatment scheme is found for IRAK1 high-expression tumors. 本发明提供了IRAK1抑制剂联合PARP抑制剂在制备抗肿瘤的药剂中的应用，涉及生物医药技术领域。本发明发现在IRAK1高表达的肿瘤中，IRAK1能促进NBS1磷酸化的发生，进而提高了DNA同源重组修复效率，导致PARP抑制剂治疗不敏感；如果抑制IRAK1酶活，会使NBS1磷酸化减低，同源重组修复效率下降，此时联合PRAP抑制剂的使用，具